JPS61172822A - Ionized calcium preparation for oral administration containing electrolyzed oyster shell - Google Patents
Ionized calcium preparation for oral administration containing electrolyzed oyster shellInfo
- Publication number
- JPS61172822A JPS61172822A JP1360885A JP1360885A JPS61172822A JP S61172822 A JPS61172822 A JP S61172822A JP 1360885 A JP1360885 A JP 1360885A JP 1360885 A JP1360885 A JP 1360885A JP S61172822 A JPS61172822 A JP S61172822A
- Authority
- JP
- Japan
- Prior art keywords
- ionized calcium
- oyster shell
- electrolyzed
- preparation
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【発明の詳細な説明】
本発明は、イオン化カルシウムの服用時の口とか胃の粘
膜に対する刺激性、不快性を少なくした経口カルシウム
製剤に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to an oral calcium preparation that reduces irritation and discomfort to the mucous membranes of the mouth and stomach when ionized calcium is taken.
カルシウムは丈夫な骨や歯をつくるだめの成分だけでな
く、血液の浄化や、脳、神経、心臓、筋肉など人間の生
命を維持してゆくのに重要な働きをしていることが、最
近の研究でつぎつぎと解明されている。It has recently been discovered that calcium is not only a building block for strong bones and teeth, but also plays an important role in purifying the blood and maintaining human life in areas such as the brain, nerves, heart, and muscles. This has been elucidated one after another through research.
とくに成人病といわれる病気のほとんどが、カルシウム
などのミネラル不足や原因であると多くの学者が指摘し
ているし、厚生省の発表によっても、今日の一億半健康
の状態はカルシウムの不足に基因するものであることが
明らかになっている。In particular, many scholars have pointed out that most of the so-called adult diseases are caused by a lack of minerals such as calcium, and the Ministry of Health and Welfare has also announced that the health status of 100 million and a half people today is due to a lack of calcium. It has become clear that it will.
人間の主なカルシウム補強源は、イオン化されたカルシ
ウムが含まれている牛乳や水などであるが、日本の水は
、日本国土産体が火山土質であるため、ヨーロッパの水
にくらべてb程度のカルシウムしか含まれていないため
、日本人は慢性的なカルシウム不足に陥シ、先に述べた
ような各機能に障害をもたらすことになる。The main source of calcium supplementation for humans is milk and water, which contain ionized calcium, but since Japan's national treasure is made of volcanic soil, the water in Japan is only about B compared to water in Europe. Because it contains only 100% of calcium, Japanese people suffer from a chronic calcium deficiency, which leads to impairments in the various functions mentioned above.
そこで、この半健康状態を改善するには、カルシウムを
充分補うことが必要なのはいうまでもないが、カルシウ
ムを多く含んだ魚の骨や海草などを食べても、体内では
殆んど吸収されない。もともとカルシウムはイオンの状
態で存在する元素なので、体内でもイオン化しなければ
吸収されないからである。Therefore, it goes without saying that to improve this semi-healthy state, it is necessary to supplement with sufficient calcium, but even if you eat fish bones and seaweed that contain a lot of calcium, very little of it is absorbed by the body. Calcium is an element that originally exists in the form of ions, so it cannot be absorbed by the body unless it is ionized.
カルシウム製剤についてはその吸収の機構が複雑である
ため、従来その剤形や製法にあまり工夫がなされていな
かったが、大量のカルシウムを有効に吸収させしかも不
快感を全く消失させるためには今后更にいくつかの問題
点を解決しなければならないとされていた。Due to the complicated absorption mechanism of calcium preparations, not much effort has been made in the formulation or manufacturing method, but in order to effectively absorb large amounts of calcium and completely eliminate discomfort, more efforts have now been made. Several problems had to be resolved.
そこで、最近開発されだしたのが、イオン化されたカル
シウム製剤である。Therefore, ionized calcium preparations have recently been developed.
本出願人も、この状況にかんがみ、先に牡蛎殻を電解精
製した電解ボレイを原料とし、その他のミネラルを含む
カルシウム製剤を開発した。In view of this situation, the present applicant has previously developed a calcium preparation containing other minerals, using electrolytic borey obtained by electrolytically refining oyster shells as a raw material.
この電解ポレイイオン化カルシウムは財団法人 日本食
品分析センターによる電気伝導率の測定によって、イオ
ン化濃度が10,000μS/1117F!(25℃)
という高い測定値を示し、他の市販のカルシウム製剤の
イオン化濃度81〜790μS/α(25℃)にくらべ
抜群の腸内吸収性を示し、現在も各大学の付属病院をは
じめとする医療機関において、積極的にカルシウム不足
による病気の予防、治療に採用されている。The ionization concentration of this electrolyzed polay ionized calcium was determined to be 10,000μS/1117F by measuring the electrical conductivity by the Japan Food Research Center Foundation! (25℃)
It has a high measurement value of 81 to 790μS/α (at 25℃) of other commercially available calcium preparations, and has excellent intestinal absorption, and is currently used in medical institutions such as university hospitals. It is actively used for the prevention and treatment of diseases caused by calcium deficiency.
電解ポレイイオン化カルシウムについての腸管吸収につ
いては、医療ジャーナル社発行「製薬工場」第4巻第1
2号(1984)に、神戸大学医学部第3内科藤田拓男
教授が報告されている。Regarding the intestinal absorption of electrolyzed ionized calcium, please refer to "Pharmaceutical Factory", Vol. 4, No. 1, published by Medical Journal Co., Ltd.
No. 2 (1984), Professor Takuo Fujita of the Third Department of Internal Medicine, Kobe University School of Medicine reported.
ところで、この腸管吸収性のすぐれた電解ポレイイオン
化カルシウム製剤には、空腹時に服用すると人によって
は特に老人、胃弱者は刺激性を感じ、嘔吐窓を伴なうと
いう欠点があった。However, this electropolymerized ionized calcium preparation, which has excellent intestinal absorption, has the disadvantage that when taken on an empty stomach, some people, especially the elderly and people with weak stomachs, may find it irritating and may be accompanied by a window of vomiting.
本発明者は、この原因が電解ボレイイオン化カルシウム
の強アルカリという、Hにあることをつきとめ、鋭意研
究を重ねた結果、本発明に到達したものである。The present inventor found that the cause of this was due to H, which is a strong alkali of electrolytic ionized calcium, and as a result of extensive research, the present invention was achieved.
すなわち、PH10以上の強アルカリ性を示す電解ボレ
イイオン化カルシウムを服用し一度にとけると急に強い
アルカリ性になシ胃内の酸(PH1〜2)と急激に中和
反応を起こし、胃内の酸性状況がバランスを欠き、それ
が嘔吐窓、胃痛となって表われるものと考えられる。In other words, if you take electrolyzed boley ionized calcium that is strongly alkaline with a pH of 10 or higher and dissolve it all at once, it will suddenly become strongly alkaline, causing a rapid neutralization reaction with the acid in the stomach (PH 1-2), and reducing the acidic situation in the stomach. This is thought to result in a lack of balance, which manifests itself in vomiting windows and stomach pain.
そこで電解ボレイイオン化カルシウムのPHを10〜4
程度の弱ア゛ルカリ性とし胃内で徐々にとかすか、急に
とけても中和させるようにすることにより嘔吐窓、胃痛
を伴うような変化は表われずに済むのではないかという
結論に至った0そこで、各種の、H調整剤を検討した結
果、電解ボレイイオン化カルシウムの腸管吸収性を低下
させることなく、PHを調整することのできるのは、還
元麦芽糖とクエン酸であることをつきとめ、本発明を完
成したものである。Therefore, the pH of electrolytic boley ionized calcium was set to 10 to 4.
The conclusion was that by making it slightly alkaline and dissolving it gradually in the stomach, or neutralizing it even if it suddenly dissolves, changes such as the vomiting window and stomach pain may not occur. As a result of examining various H adjusters, we found that reduced maltose and citric acid can adjust the pH without reducing the intestinal absorption of electrolyzed ionized calcium. This has led to the completion of the present invention.
還元麦芽糖およびクエン酸の電解ボレイイオン化カルシ
ウムに対する配合割合(重量比)は、それほど厳密では
ないが、目安として電解ボレイイオン化カルシウム1に
対して還元麦芽糖の場合は0.5〜3、クエン酸の場合
は1〜2であることが好ましく、還元麦芽糖とクエン酸
を併用しても同様の効果が得られた。The mixing ratio (weight ratio) of reduced maltose and citric acid to electrolytic boley ionized calcium is not very strict, but as a guide, it is 0.5 to 3 for reduced maltose and 0.5 to 3 for citric acid to 1 part electrolytic boley ionized calcium. is preferably 1 to 2, and similar effects were obtained even when reduced maltose and citric acid were used together.
処方例 l。Prescription example l.
電解ボレイイオン化カルシウム 30%(重量)粉
未還元麦芽糖 70%以上を加水混
合して造粒し、乾燥したのち錠剤機にて打錠する。Electrolytic Borei ionized calcium 30% (by weight) Powder Unreduced maltose 70% or more is mixed with water, granulated, dried, and then tableted using a tablet machine.
処方例 2゜
電解ポレイイオン化カルシウム50%に対して、粉未還
元麦芽糖を50%にし、処方lと同様にして打錠した。Formulation Example 2゜Polymerized 50% ionized calcium and 50% powdered unreduced maltose were compressed into tablets in the same manner as in Formulation 1.
処方例 3゜
電解ボレイイオン化カルシウム40%に対して、クエン
酸を60%にし、処方1と同様にして打錠した。Formulation Example 3゜Electrolytic Borei 40% ionized calcium and 60% citric acid were compressed into tablets in the same manner as in Formulation 1.
処方例 4゜
電解ボレイイオン化カルシウム33%に対して、粉未還
元麦芽糖を50%、クエン酸を17%にし、処方1と同
様にして打錠した。Formulation Example 4゜Electrolytic Borei ionized calcium was 33%, powdered unreduced maltose was changed to 50%, and citric acid was changed to 17%, and the tablets were compressed in the same manner as in Formulation 1.
以上の処方により見られた電解ボレイイオン化カルシウ
ム製剤は、いずれも服用時に従来のような不快感が感じ
られなかった。All of the electrolytic Borei ionized calcium preparations prepared according to the above formulations did not cause discomfort unlike conventional ones when taken.
特許出願人 株式会社 富士企画
手続補正書(自発差出)
昭和60年6月 4日
特許庁長官 志 賀 学 殿
1、事件の表示
昭和60年特許願第13608号
2、発明の名称
経口電解ボレイイオン化カルシウム製剤3、補正をする
者
事件との関係 特許出願人
住所 東京都渋谷区代々木5丁目59番4号名称
株式会社 富 士 企 画
4、代理人
別紙記載の通り
7、 補正の内容
(1)明細書第1頁第18行「ミネラル不足や」を「ミ
ネラル不足が」と補正する。Patent Applicant: Fuji Planning Co., Ltd. Written Amendment to Procedural Procedures (voluntarily submitted) June 4, 1985 Manabu Shiga, Director General of the Patent Office1, Indication of the Case 1985 Patent Application No. 136082, Name of the Invention Oral Electrolytic Boray Ionization Calcium Preparation 3, Relationship with the Amendment Case Patent Applicant Address 5-59-4 Yoyogi, Shibuya-ku, Tokyo Name
Fuji Planning Co., Ltd. 4. As stated in the agent's attachment 7. Contents of the amendment (1) On page 1, line 18 of the specification, "Mineral deficiency" is amended to read "Mineral deficiency."
(2) 同第2頁第4行「牛乳や水」を「牛乳や自然
な水」と補正する。(2) On page 2, line 4, "milk and water" is corrected to "milk and natural water."
(3) 同第3頁第5行〜7行目「本出願人も・・・
開発した。」を「本出願人も、この状況にかんがみ、先
に牡端殻を電解精製したミネラルを含む電解ボレイイオ
ン化カルシウム製剤を開発した。」と補正する。(3) Page 3, lines 5 to 7 “The applicant also...
developed. '' should be amended to ``In view of this situation, the present applicant has also developed an electrolytic boley ionized calcium preparation containing minerals obtained by electrolytically refining bull's-tail shells.''
(4)同第4頁第15〜16行目「そこで・・・・徐々
に」を「そこで電解ボレイイオン化カルシウムを徐々に
」と補正する。(4) On page 4, lines 15 and 16, "there...gradually" is corrected to "gradually apply electrolytic ionized calcium there."
(5)同第5頁第15〜16行目「以上を・・・・打錠
する。」を「以上を一般の製剤方法により打錠する。」
と補正する。(5) On page 5, lines 15 and 16, "the above is...compressed into tablets." is replaced with "the above is compressed into tablets using a general formulation method."
and correct it.
Claims (1)
たはクエン酸を配合したことを特徴とする経口電解ボレ
イイオン化カルシウム製剤。An oral electrolytic Borei ionized calcium preparation characterized by blending electrolytic Borei ionized calcium with reduced maltose and/or citric acid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1360885A JPS61172822A (en) | 1985-01-29 | 1985-01-29 | Ionized calcium preparation for oral administration containing electrolyzed oyster shell |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1360885A JPS61172822A (en) | 1985-01-29 | 1985-01-29 | Ionized calcium preparation for oral administration containing electrolyzed oyster shell |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS61172822A true JPS61172822A (en) | 1986-08-04 |
JPH0113691B2 JPH0113691B2 (en) | 1989-03-07 |
Family
ID=11837941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1360885A Granted JPS61172822A (en) | 1985-01-29 | 1985-01-29 | Ionized calcium preparation for oral administration containing electrolyzed oyster shell |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS61172822A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62263126A (en) * | 1986-05-12 | 1987-11-16 | Fuji Kikaku:Kk | Ionized calcium preparation for oral administration produced from electrolyzed oyster shell |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5148467A (en) * | 1974-10-23 | 1976-04-26 | Kyoko Ootsu | |
JPS5585385A (en) * | 1978-12-22 | 1980-06-27 | Mitsuma Miyoshi | Powdered food and drink |
JPS5931710A (en) * | 1982-08-17 | 1984-02-20 | Masaki Takahara | Drinking solution for supplying calcium |
-
1985
- 1985-01-29 JP JP1360885A patent/JPS61172822A/en active Granted
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5148467A (en) * | 1974-10-23 | 1976-04-26 | Kyoko Ootsu | |
JPS5585385A (en) * | 1978-12-22 | 1980-06-27 | Mitsuma Miyoshi | Powdered food and drink |
JPS5931710A (en) * | 1982-08-17 | 1984-02-20 | Masaki Takahara | Drinking solution for supplying calcium |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62263126A (en) * | 1986-05-12 | 1987-11-16 | Fuji Kikaku:Kk | Ionized calcium preparation for oral administration produced from electrolyzed oyster shell |
JPH0113692B2 (en) * | 1986-05-12 | 1989-03-07 | Fuji Kikaku Kk |
Also Published As
Publication number | Publication date |
---|---|
JPH0113691B2 (en) | 1989-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5914129A (en) | Analgesic composition for treatment of migraine headaches | |
US3337404A (en) | Effervescent potassium composition | |
US20170080024A1 (en) | Effervescent gargle tablet and method of using same | |
US4959222A (en) | Magnesium additive for nutrients, feed, and medicaments | |
US4387093A (en) | Arthritis treatment | |
JPH06506682A (en) | Oral pharmaceutical composition for treating upper gastrointestinal tract symptoms | |
ES2192136B1 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF OSTEOPOROSIS. | |
JPH09183732A (en) | Potassium dominant non-solution pill and health promotion using the pill | |
JPS61172822A (en) | Ionized calcium preparation for oral administration containing electrolyzed oyster shell | |
US4539315A (en) | Sublingually absorbable nontoxic aspirin composition | |
JPH0563452B2 (en) | ||
US4650668A (en) | Composition for relieving toothache pain and other forms of intense pain | |
JPS62263126A (en) | Ionized calcium preparation for oral administration produced from electrolyzed oyster shell | |
US4446132A (en) | Nontoxic aspirin composition | |
RU2176893C2 (en) | Biologically active food supplement "dnaavit" | |
JP2665764B2 (en) | Calcium aqueous solution | |
JP6355806B1 (en) | A therapeutic agent for constipation containing lactulose as an active ingredient | |
JP2002201135A (en) | Composition for epigastrium comprising lactulose | |
RU2205648C1 (en) | "calcisan" composition for prophylaxis and maintenance therapy in case of gastro-intestinal diseases | |
RU2026673C1 (en) | Agent for enuresis treatment | |
RU1804850C (en) | Method for treatment influenza | |
Van Dyke | Medical problems in infants and young children with Down syndrome: Implications for early services | |
Srilakshmi et al. | INTERNATIONAL RESEARCH JOURNAL OF PHARMACY | |
UA141902U (en) | METHOD OF CORRECTION OF MAGNESIUM DEFICIENCY IN THE BODY DURING MASSAGE PROCEDURE | |
KR20200083971A (en) | Calcium supplement composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EXPY | Cancellation because of completion of term |